Early evidence suggests CBD could help clinicians treat pericarditis, myocarditis and other significant heart conditions. Additional research is still required, however, including many more clinical trials.

Cytokinetics has secured FDA approval for aficamten, its new drug for the treatment of symptomatic obstructive HCM. Aficamten will be sold under the brand name Myqorzo. 

These most recent recalls focus on a series of maintenance issues. In 2024, the FDA advised customers to transition away from the two devices and find alternative treatment options.

The Barostim device from CVRx continues to gain momentum as a go-to heart failure treatment. A free webinar is scheduled to examine the device's new CPT codes, which go into effect in 2026.

Cardiologists often use the word “stable” when describing a heart failure patient who is recovering or showing signs of improvement. That word, however, could be giving patients a false sense of security—and it could even do harm to their long-term health.